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immune thrombocytopenia patients: a retrospective study
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Background/aim: Immune thrombocytopenia (ITP) is treated by corticosteroids and/or intravenous immune globulin as the first line
treatment when necessary. Mean platelet volume (MPV) is a marker of platelet production and function. In this study, we aimed to
search the relationship between the MPV and the treatment response in ITP patients and it was hypothesized that MPV can be used as
a predictor of the response.
Materials and methods: The 70 newly diagnosed adult primary ITP patients and 70 of healthy people were included. MPV between ITP
and healthy population, MPV in the diagnosis and after the treatment between the responders and the nonresponders were compared.
Results: The responders had significantly higher MPV and the nonresponders had significantly lower MPV than the healthy population
(11.09 and 10.21 fL, P = 0.03; 9.38 and 10.21 fL, P = 0.001). MPV in the diagnosis was significantly higher in the responders than the
nonresponders (11.09 and 9.38 fL, P = 0.005). MPV significantly changed after the treatment in the responders (11.09 to 9.32 fL, P =
0.004).
Conclusion: MPV can be used as a predictor of early response to the first line treatment in newly diagnosed adult primary ITP patients.
Key words: Immune thrombocytopenia, first line treatment, response, mean platelet volume

1. Introduction
Immune thrombocytopenia (ITP) is an acquired
thrombocytopenia which is defined by the platelet count
(PLT) is less than 100 × 109/L. Primary ITP is caused by
antibody and T cell mediated destruction of the platelets
and impaired megakaryopoiesis, whereas the secondary
ITP is due to underlying disorders. Due to the immune
pathophysiological mechanism of the primary ITP, patients
are initially treated by corticosteroids and intravenous
immune globulin (IVIG), when they need the treatment [1].
Although the platelet count increases in 3–5 days after the
treatment, there is no available study that may investigate
the predictive factors of the short-term response to the
first line therapy. Mean platelet volume (MPV), which is
easily available in clinical practice, is a marker of platelet
function [2]. Several studies have investigated the MPV
value in the diagnosis and differential diagnosis of the ITP
and hypoproliferative thrombocytopenia [3–8], relapse of
the ITP [9,10] and thrombocytosis [11]. Although these

studies have revealed important aspects of the MPV and
ITP, they have not investigated the relationship between
the MPV and short-term treatment response to the first
line therapy. Moreover, some have insufficient study
design.
In this study, a retrospective search was implemented in
newly diagnosed adult primary ITP patients. We aimed to
search the relationship between the MPV and response to
the first line therapy hypothesizing the MPV as a possible
predictive factor of the treatment response.
2. Materials and methods
2.1. Subjects
A power calculation (GPower 3.1 software) indicated the
need for 30 patients to have 80% power to detect a 2 fL
difference in MPV (for example, 10 fL in one group and 12
in the other, with the standard deviation of 3). Difference
and standard deviation were chosen according to ITP and
healthy population values in the previous studies [6,12].
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Patients were retrospectively screened in the patient
database of Ankara University, Faculty of Medicine
between the January of 2014 and the June of 2017. The last
recommendations of the American Society of Haematology
and International Working Group were applied for the
diagnosis, treatment, and response evaluation [1].
Briefly, the diagnosis of ITP was made by evaluation
of history, examination of the patient, review of the
peripheral smear and with some additional limited tests
(HBsAg, Anti-HCV, Anti-HIV and H. pylori antigen stool
tests, direct antiglobulin testing, thyroid function tests).
Bone marrow examination was performed when it was
needed.
A total of 250 patients diagnosed with ITP were
screened in the database. The newly diagnosed outpatient
ITP patients (diagnosed less than 3 months), treated by
the first line treatment (methylprednisolone, intravenous
immune globulin) and patients whose planned data
were available were included. Secondary ITP, drug
induced thrombocytopenia, HBsAg, anti-HCV, anti-HIV
positive and H. pylori antigen positive patients, pregnant
and hospitalized patients, patients with severe organ
dysfunction, patients using any medication regularly
and patients having comorbid disease that can affect
the MPV (diabetes mellitus, thyroid dysfunction, renal,
liver, and cardiovascular disease) were excluded (Figure
1).The patients who were given platelet transfusion at
the presentation were not excluded (because platelet life
span is 7–10 days and transfused platelets have shorter life
span. In this study, MPV measurements were made before
transfusion and at least 1 week after the transfusion.)
Patients were treated by oral corticosteroid (1 mg/kg/d
methylprednisolone) or corticosteroid plus 1 g/kg/d IVIG
for 2 days. IVIG was initiated on the day of the treatment
decision together with corticosteroid and corticosteroid
was continued after the IVIG until the second visit for the
response evaluation. The treatment decision was made by
the responsible doctor at that time. The indications for
the treatment were low platelet count and/or clinically
significant bleeding.
The response was evaluated beginning from 1 until the
3 weeks after treatment initiation in the outpatient visit.
Patients were grouped as responders and nonresponders
according to the 1 of 2 response criteria: 1) platelet counts
> 100 × 109/L measured on 2 occasions 7 days apart, 2)
platelet counts > 30 × 109/L and a greater than twofold
increase in platelet count from baseline, measured on 2
occasions 7 days apart.
An independent population of healthy people was
included as a control group.
Approval of ethical committee was obtained from
Ethics Committee of Ankara University Faculty of
Medicine in compliance with the Helsinki Declaration.

Figure 1. Selection of the study population.

2.2. Methods
MPV was measured in the diagnosis and response
evaluation. Tourniquets were used for drawing blood and
collections were completed in less than 1 min. Venous
blood was collected into 2 mL EDTA tube and analysed
in less than 2 h. Platelet count and MPV were measured
by the implementation of 2-angle laser light scattering
method in ADVIA 2120i Hematology System (Siemens
Healthcare Diagnostics, Tarrytown, NY, USA). Coefficient
of variation (both within and between assays) was 1.4%.
Internal quality control procedure (ADVIA TESTpoint
Hematology Controls) includes 3 different levels (low,
normal, and high) and was assessed according to Westgard
Rules. The reference ranges in the lab for platelet count and
MPV were 150–400 × 109/L and 6.5–10.5 fL, respectively.
The age, sex, presenting symptom, baseline PLT and
MPV in the diagnosis and PLT, MPV in the response
evaluation were recorded.
The baseline PLT, MPV between the ITP and healthy
population; PLT, MPV between the responders and
the nonresponders in baseline and after the treatment;
the MPV changes after the treatment in the responder
and nonresponders, sensitivity, specificity, positive and
negative predictive value of the MPV were compared and
evaluated.
2.3. Statistical analyses
The median (minimum and maximum), mean (standard
deviation (SD)), number and percentage were used as
descriptive statistics. The difference in means between 2
groups was evaluated by Student’s t test. The chi square test

799

AKKUŞ et al. / Turk J Med Sci
was used for the difference between proportions. Pairedsamples T test was used to evaluate the difference between
before and after the treatment measurements. Receiver
operating characteristic (ROC) curve was used to describe
the performance of a diagnostic test. The area under
the corresponding curve was calculated by Hanley and
McNeil [13]. The sensitivity and specificity were calculated
under various cut-off value. All P values were based on a
2-tailed test of significance (P = 0.05). Analyses were made
by using SPSS version 22 (IBM Corp., Armonk, NY, USA).
3. Results
3.1. Patients and characteristics
Among the 250 patients screened, 70 patients were
included in the study according to the including-excluding
criteria (Figure 1).
The age, sex, presenting symptom, PLT and MPV in
the diagnosis of the study and healthy population are
given in Table 1. The median age of the ITP group was
41 (19–80) and there was female dominancy (62.9%).
Fifty-three percent of the patients were presented by skin
bleeding (petechiae, purpura, and ecchymosis), the 31%
was detected incidentally. Mucosal bleeding (epistaxis,
gum bleeding, gastrointestinal bleeding) was 13%. The
51% of the patients were also given the IVIG therapy at the
beginning of corticosteroid treatment (Table 1).
3.2. ITP/healthy population
We first evaluated the MPV in the ITP and healthy groups.
The median platelet count was 18 × 109/L (1–63 × 109 / L)
and MPV was 10 fL (4.8–21.6) in the ITP group. Median

MPV was 10.2 fL (7.8–12.3) in the healthy group. The age,
sex, and MPV were not significantly different between the
ITP and healthy group (P = 0.76 for the MPV, CI: –0.74–
0.54) (Table 1). We evaluated the MPV in the diagnosis of
responders and nonresponders separately comparing with
the healthy population. The responders had significantly
higher MPV than the healthy population (11.09 and
10.21, P = 0.03, CI: 0.71–1.68). The nonresponders had
significantly lower MPV than the healthy population (8.95
and 10.21, P = 0.001, CI: 0.32–1.33).
3.3. Responders/nonresponders
Secondly, we evaluated the MPV difference between the
responders and the nonresponders in the diagnosis and
after the treatment, respectively. The 30 of 70 patients (43%)
responded the treatment according to response criteria.
There was not any difference in age, sex, and platelet count
in the diagnosis and no difference in the IVIG treatment
between the responders and the nonresponders. However,
MPV in the diagnosis was significantly higher in the
responders than the nonresponders (11.09 and 9.38 fL, P
= 0.005, CI: 0.53–2.88). There was not any difference in
MPV after the treatment between the responders and the
nonresponders (9.32 and 9.4 fL, P = 0.85, CI: –0.94–0.78)
(Table 2).
Assessing the whole study population, it was found
that the MPV value significantly changed after the
treatment (10.11 fL to 9.37 fL, P = 0.014, CI: 0.15–1.33).
By analysing the responder group and the nonresponder
group separately; there was a significantly decrease of the
MPV in the responder group after the treatment, while

Table 1. Baseline characteristics of the ITP patients and the healthy population.
Study population
(n = 70)

Healthy population
(n = 70)

P

Age, year (median, min–max)

41(19–80)

40.5 (21–89)

0.74

Female, n (%)

44 (62.9%)

34 (48.6%)

Male, n (%)

26 (37.1%)

36 (51.4%)

PLT, × 109/L (median, min–max)

18 (1 - 63)

260 (157 - 373)

< 0.001

MPV, fL (mean, SD)

10.11 (2.56)

10.21 (0.91)

0.76

Skin bleeding, n (%)

37 (53%)

Mucosal bleeding, n (%)

9 (13%)

Organ bleeding, n (%)

2 (3%)

Incidental, n (%)

22 (31%)

Plus IVIG, n (%)

36 (51%)

Total response rate (%)
Responder, n
Nonresponder, n

43%
30
40

0.08

PLT: platelet, L: litre, MPV: mean platelet volume, fL: femtoliter, IVIG: Intravenous immunoglobulin.
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Table 2. Characteristics of the responders and the nonresponders.
Responder
(n = 30)

Non-responder
(n = 40)

P

Age, year (median, min–max)

41 (23–79)

40 (19–80)

0.48

Sex
Female, n (%)
Male, n (%)

18 (60%)
12 (40%)

26 (65%)
14 (35%)

0.66

Plus IVIG, n (%)

13 (43%)

23 (57%)

0.24

PLT in the diagnosis, × 109/L (mean, SD)

17.6 (11.4)

24.7 (19.04)

0.07

MPV in the diagnosis, fL (mean, SD)

11.09 (3.12)

9.38 (1.76)

0.005

PLT after the treatment, × 10 /L (mean, SD)

149.8 (115)

22.9 (18.4)

< 0.001

MPV after the treatment, fL (mean, SD)

9,32 (1.82)

9,4 (1.76)

0.85

P*

0,004

0,928

9

PLT: platelet, L: litre, MPV: mean platelet volume, fL: femtoliter, IVIG: Intravenous immunoglobulin.
*P value for the difference between pre and post treatment MPV.

there was not any significant change in the nonresponder
group (P = 0.004 CI: 0.62–2.91; P = 0.92 CI: –0.52–0.47,
respectively) (Table 2).
The results of those analyses show that MPV value was
higher in the diagnosis in the responder group and also
it decreased after the treatment in the responders while it
did not change in the nonresponder group (Table 2).
3.4. Predictive role of the MPV in the diagnosis
As the MPV was higher in the responder group in the
diagnosis and it decreased after the treatment, we
questioned whether the MPV in the diagnosis may be
used for the prediction of the treatment response or not.
The ROC curve analysis was implemented for the
MPV in the diagnosis and the response to the first line
therapy. The area under the curve (AUC) was 0.69 (P =
0.006, CI: 0.56–0.82) (Figure 2). The sensitivity for the
responders was calculated for MPV > 8.85 fL (sensitivity:
83.3%, specificity: 50%, negative predictive value (NPV):
80%). The specificity was calculated for MPV > 11.15
fL (sensitivity: 40%, specificity: 80%, positive predictive
value (PPV): 60%). For the cut-off value of 12.5 fL for the
MPV, the specificity was 97.5% and PPV was 83.3%. For
the cut-off value of 13 fL, the specificity and the PPV was
100%. In this cut-off value of > 13 fL, odds ratio was 8.99
for the responders (P = 0.003).
4. Discussion
In this study, the objective was to evaluate the relationship
between the MPV and response to the first line treatment
in newly diagnosed adult ITP patients. Response rate was
similar to the previous studies [14,15]. MPV was higher
in the diagnosis in the responders and also it decreased

Figure 2. ROC curve of the MPV in the diagnosis and the
response AUC: 0.69.

after the treatment in the responders while it did not
change in the nonresponders. When the MPV is higher
than 13 fL, the specificity and positive predictive value
were 100% for the response, odds ratio was 8.9.
A few previous studies have investigated the
relationship between the MPV and ITP. MPV was found
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higher in ITP than aplastic anaemia [3], chemotherapyrelated myelosuppression [4], myelodysplastic syndrome
[8] and other hypoproductive thrombocytopenia
[6]. MPV was also found higher in ITP than healthy
controls [6,12]. However, diagnostic criteria of the
ITP, confounding factors and excluding criteria have
not been indicated in these studies. One study with 81
patients shows that MPV is normalized after first line
treatment and is gradually increasing before the first
and second relapses and is normalized again after the
second line treatment [9]. But the patient population
of this study is heterogeneous and response data of
the patients are not certain. Another study with the
233 newly diagnosed ITP patients shows a nonlinear
relationship between MPV and ITP relapse. The MPV
was an independent risk factor of the ITP relapse when
it is less than 21 fL [10]. Both of these studies take into
account the long term follow up, like for 6 months. In
daily outpatient practice, it is important to know which
patient will respond after 1 to 3 weeks, especially if the
patient has bleeding or very low platelet count which can
cause life threatening bleeding. In our study, we aimed to
predict which patients will respond to the therapy in the
next outpatient control which is about 1 to 3 weeks later.
We may suggest that if the cut-off is 12.5 fL for the MPV,
the higher MPV than this value may predict the response
and patient can be followed safely outpatient with high
specificity.
The pathophysiology of ITP includes antiplatelet
antibodies and dysregulated immune system, especially
T cells. The 60% to 70% of the patients have antibodies
which cause platelet destruction and impaired
megakaryopoiesis. Patients having no antibodies have
abnormal T cells that cause platelet destruction or
diminish production [1]. Each pathologic mechanism
plays varying roles in each patient and because of this
pathophysiologic heterogeneity, it has not been possible
so far to predict the mechanism from clinically available
information and to integrate this information with
treatment decisions [16].
It is thought that peripheral platelet destruction
leads premature and large circulation platelets because
of the increased production [7]. So, it is assumed that
MPV is high in the ITP patients. The previous studies
indicated that MPV may be used to differentiate between
hypo and hyper productive thrombocytopenia and ITP
patients have higher MPV than the hypoproductive
thrombocytopenia (aplastic anaemia, myelodysplasia)
[3–8]. However, different mechanisms may be dominant
in different patients and this may cause different MPV
values in patients.
Corticosteroids
suppress
reticuloendothelial
phagocytic function and reduce antibody production,
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leading to a reduced platelet destruction [17]. The IVIG
inhibits platelet phagocytosis, suppresses antiplatelet
antibody production and neutralizes autoantibodies
[18]. Corticosteroids cause a decrease in IgG and IgA
levels in 2–4 weeks of the treatment and no change in
IgM levels [19,20]. Thus, main therapeutic mechanism
of corticosteroids in the ITP is their inhibitory effect on
antibody mediated platelet destruction [17].
By thinking that the first line therapy primarily
effects antibody mediated platelet destruction [17] and
the MPV can be different according to the underlying
mechanism of the ITP; it may be stated that the MPV
may predict the underlying dominant mechanism and
forms an indirect relationship between the underlying
mechanism and the treatment response. According
to our results, we hypothesize 2 subgroups of the ITP
patients: the first line therapy is beneficial in patients
whose dominant mechanism is destruction of the
platelets. These patients have higher level of MPV in the
diagnosis (because of the destruction of the platelets and
newly produced large circulating platelets) and the MPV
decreases after the response (when destruction stops).
The second group is that the underlying mechanism is
the impaired production. These patients have a low level
of MPV in the diagnosis and does not response to the
first line therapy and the MPV does not change after the
treatment.
The strengths of our study were strict including and
excluding criteria. Because the time interval among the
measurements was short, the heterogeneity and incorrect
data were decreased. It was aimed to suggest a solution
for a daily practical problem. Moreover, our study can
arise a new hypothesis about the subpopulations of the
ITP patients according to pathogenesis and the treatment
response.
The limitation of our study is its retrospective design
and the low sample size. The study does not show the
long-term relapse and the second line treatment data.
In conclusion, the MPV may be used as a predictor of
the early response to the first line treatment in the newly
diagnosed adult primary ITP patients. Future studies can
validate or reject these results by using a larger sample size
and search for the relationship between the underlying
mechanism, MPV, and the treatment response.
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